Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapies to treat substance use and eating disorders.

Addiction is not a character flaw – it is now recognized as a chronic brain disease with the potential for both recovery and relapse, and we must treat it with the same skill and compassion with which we approach heart disease, diabetes, and cancer (2016 Surgeon General’s Report). It is the most severe manifestation of a substance use disorder (SUD), characterized by significant impairments in health, social function and control over substance use.  Similar to other chronic brain diseases, addiction can and should be treated with medications alongside supportive therapy when appropriate.

Moreover, there is compelling evidence of a commonality in the brain pathways responsible for the pleasurable response to food and the core pathways mediating the rewarding properties of drugs such as morphine and heroin.  The neurobiological and behavioral similarities between eating disorders and drug addictions provide compelling evidence that eating disorders should be viewed and treated as an addiction.

In response to this growing public health crisis, Opiant is developing a robust clinical pipeline of products to treat substance use and eating disorders.

Opiant CEO Roger Crystal on Fox Business Network with Liza Claman

October 26, 2017 – Opiant CEO Dr. Roger Crystal discusses the Company’s role in combating addiction and the opioid crisis, a “public health emergency” as declared by President Trump.

Opiant CEO Roger Crystal Testifies Before the President’s Commission

September 27, 2017 – Opiant CEO Dr. Roger Crystal testifies before the President’s Commission on Combating Drug Addiction and the Opioid Crisis.